Co-Diagnostics, Inc. (CODX) vs GT Biopharma, Inc. (GTBP)
A side-by-side comparison of Co-Diagnostics, Inc. and GT Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CODX
Co-Diagnostics, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 12:09 PM EDT
GTBP
GT Biopharma, Inc.
$6.30HealthcareDelayed quote: Oct 6, 2026, 12:09 PM EDT
Total return — CODX vs GTBP
growth of $100 · dividends reinvested · last 9yCODX -99.4% (-43.0%/yr)GTBP -100.0% (-64.7%/yr)CODX compounded faster over this window
Log scale — wide-divergence pair
CODX GTBP
CODX vs GTBP: by the numbers
- •GTBP is the larger company ($8M vs $7M market cap).
- •Both run net losses; GTBP's is the smaller (0.00% vs -6523.04% net margin).
Metrics side by side
Valuation
| Metric | CODX | GTBP |
|---|---|---|
| P/S ratio | 9.23 | N/A |
| P/B ratio | 0.52 | 2.23 |
Profitability
| Metric | CODX | GTBP |
|---|---|---|
| Gross margin | 64.28% | 0.00% |
| Operating margin | -5025.53% | 0.00% |
| Net margin | -6523.04% | 0.00% |
| ROE | -370.16% | -618.74% |
| ROIC | -219.15% | -457.75% |
Growth (annualized)
| Metric | CODX | GTBP |
|---|---|---|
| Revenue CAGR (5Y) | -62.43% | N/A |
| Total return CAGR (5Y) | -66.53% | -73.13% |
Frequently asked
- How have CODX and GTBP total returns compared?
- Over the past 5 years, CODX delivered -66.53% and GTBP delivered -73.13% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.